XOMA Royalty (NASDAQ:XOMA) Shares Cross Above 200-Day Moving Average – Here’s What Happened

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $32.25 and traded as high as $42.16. XOMA Royalty shares last traded at $42.00, with a volume of 105,495 shares changing hands.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on XOMA shares. Zacks Research upgraded XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. Lucid Cap Mkts cut XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings upgraded XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 29th. Leerink Partners reissued an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. Finally, Benchmark lowered XOMA Royalty from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. One investment analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $53.75.

XOMA Royalty Stock Up 0.5%

The firm’s fifty day simple moving average is $41.30 and its 200-day simple moving average is $32.40. The company has a market cap of $528.56 million, a PE ratio of 26.85 and a beta of 0.88. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.96.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The business had revenue of $12.32 million for the quarter, compared to analysts’ expectations of $13.91 million. As a group, equities research analysts expect that XOMA Royalty Corporation will post 0.9 earnings per share for the current fiscal year.

Hedge Funds Weigh In On XOMA Royalty

Hedge funds have recently bought and sold shares of the stock. State of Alaska Department of Revenue acquired a new position in shares of XOMA Royalty during the 4th quarter valued at about $27,000. Russell Investments Group Ltd. boosted its position in shares of XOMA Royalty by 3,436.4% in the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 756 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 543 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in XOMA Royalty in the second quarter valued at approximately $116,000. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.